Blast­ing 'spec­u­la­tive com­men­tary,' GSK of­fers up­date on Zan­tac lit­i­ga­tion and vows to 'vig­or­ous­ly de­fend it­self'

GSK wants to ad­dress “spec­u­la­tive com­men­tary” about its Zan­tac lit­i­ga­tion head on.

The phar­ma gi­ant put out a lengthy state­ment af­ter a suite of an­a­lysts sound­ed the alarm on the po­ten­tial im­pact of the on­go­ing per­son­al in­jury law­suits, which trig­gered big plunges for its stock as well as that of its con­sumer health spin­out, Ha­le­on, and Sanofi, which al­so sold the drug at one point.

Zan­tac, a well-known drug used to re­duce stom­ach acid pro­duc­tion, was re­called glob­al­ly back in 2019 over “un­ac­cept­able lev­els of N-ni­troso­di­methy­lamine,” a car­cino­gen al­so known as ND­MA for short. The fol­low­ing year, the FDA and EMA rec­om­mend­ed that all prod­ucts con­tain­ing the ac­tive in­gre­di­ent ran­i­ti­dine be with­drawn.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.